Limited red blood cell (RBC) regeneration often prevents collection of sufficient blood from autologous donors. We studied the effects of subcutaneous recombinant erythropoietin (rEPO) in subjects making frequent blood donations. Six healthy iron-replete male subjects took rEPO (200 U/kg) subcutaneously daily, and donated blood (450 mL) twice a week for 3 weeks. During a control study, these su...

We investigated changes induced by four weeks of intermittent hypobaric hypoxia (IHH) at a simulated altitude of 4000-5500 m in highly trained athletes. Serum erythropoietin increased significantly (p<0.001) after the sessions of IHH, but reticulocyte and red cell parameters did not. Our IHH protocol stimulated endogenous erythropoietin secretion without producing the subsequent erythropoietic ...

Parvovirus B19 (PV B19) is a nonenveloped single-stranded DNA virus that causes wide variety of diseases ranging from benign childhood infection such as slapped-cheek syndrome to life threatening hydrous fetalis in fetuses or aplastic anemic crises patients with hemolytic anemia. In immunocompromised hosts including organ transplant recipients, PV has incorporated into red blood cell progenitor...

Despite improved survival, many preterm infants undergo subsequent neurodevelopmental impairment. To date, no neuroprotective therapies have been implemented into clinical practice. Erythropoietin, a haematopoietic cytokine used for treatment of anaemia of prematurity, has been shown to have neuroprotective and neuroregenerative effects on the brain in many experimental studies. The aim of the ...

Hypoxia is known to reduce the expression of hepcidin, the master regulator of iron metabolism. However, it is not clear whether this response is primarily related to increased erythropoiesis driven by hypoxically stimulated erythropoietin or to a more direct effect of hypoxia on hepcidin expression. The germline loss-of-function VHL(R200W) mutation is common in Chuvashia, Russia, and also occu...

Erythropoietin (EPO) is a major regulatory factor controlling red blood cell (RBC) production in humans. Although other humoral factors can alter the proliferation of committed early erythroid progenitors in vitro, no factor other than EPO has been clearly shown to induce proliferation of these cells in vivo. In a clinical trail of recombinant granulocyte colony-stimulating factor (G-CSF) and r...

Numerous uremic patients on hemodialysis have pulmonary hypertension attributable to the presence of arteriovenous fistulas, vascular calcification, and endothelial dysfunction due to alterations in the balance between vasoconstrictive and vasodilatory substances. For these reasons, the effects of recombinant human erythropoietin, a drug widely used in patients on dialysis, on the pulmonary cir...

Recombinant human erythropoietin (rHu-EPO) is used to treat anemia by activating the erythropoietin receptor (EPOR) in erythroid progenitor cells, leading to proliferation and differentiation into mature red blood cells. To allow less frequent dosing, a hyperglycosylated version of EPO has been developed with a longer half-life. In principle, an agonistic antibody targeting EPOR would offer an ...

Erythropoietin (EPO) adjusts the red cell mass to the optimal size in order to satisfy the oxygen requirement of the body. The amount of circulating EPO is regulated by oxygen sensors in the kidney, which control the secretion of EPO through feedback signals. EPO stimulates the erythroid progenitor cells at different levels to develop into mature red blood cells. In anaemia, the serum EPO conce...

Background: Oncolytic herpes simplex virus (oHSV)-based vectors lacking &gamma;34.5 gene, are considered as ideal templates to construct efficient vectors for (targeted) cancer gene therapy. Herein, we reported the construction of three single/dually-flourescence labeled and &gamma;34.5-deleted, recombinant HSV-1 vectors for rapid generation and easy selection/isolation of different HSV-Based v...